Laura L Dover1, Caleb R Dulaney1, Courtney P Williams2, John B Fiveash1, Bradford E Jackson3, Paula P Warren4, Elizabeth A Kvale5,6, D Hunter Boggs1, Gabrielle B Rocque2,5. 1. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama. 2. Department of Medicine, Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama. 3. Center for Outcomes Research, John Peter Smith Hospital Health Network, Fort Worth, Texas. 4. Department of Neurology, Division of Neuro-Oncology, University of Alabama at Birmingham, Birmingham, Alabama. 5. Department of Medicine, Division of Palliative Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 6. Birmingham VA Medical Center, Birmingham Alabama.
Abstract
Background: End-of-life care for older adults with malignant brain tumors is poorly understood. The purpose of this study is to quantify end-of-life utilization of hospice care, cancer-directed therapy, and associated Medicare expenditures among older adults with malignant brain tumors. Methods: This retrospective cohort study included deceased Medicare beneficiaries age ≥65 with primary malignant brain tumor (PMBT) or secondary MBT (SMBT) receiving care within a southeastern cancer community network including academic and community hospitals from 2012-2015. Utilization of hospice and cancer-directed therapy and total Medicare expenditures in the last 30 days of life were calculated using generalized linear and mixed effect models, respectively. Results: Late (1-3 days prior to death) or no hospice care was received by 24% of PMBT (n = 383) and 32% of SMBT (n = 940) patients. SMBT patients received late hospice care more frequently than PMBT patients (10% vs 5%, P = 0.002). Cancer-directed therapy was administered to 18% of patients with PMBT versus 25% with SMBT (P = 0.003). Nonwhite race, male sex, and receipt of any hospital-based care in the final 30 days of life were associated with increased risk of late or no hospice care. The average decrease in Medicare expenditures associated with hospice utilization for patients with PMBT was $-12,138 (95% CI: $-18,065 to $-6210) and with SMBT was $-1,508 (95% CI: $-3,613 to $598). Conclusions: Receiving late or no hospice care was common among older patients with malignant brain tumors and was significantly associated with increased total Medicare expenditures for patients with PMBT.
Background: End-of-life care for older adults with malignant brain tumors is poorly understood. The purpose of this study is to quantify end-of-life utilization of hospice care, cancer-directed therapy, and associated Medicare expenditures among older adults with malignant brain tumors. Methods: This retrospective cohort study included deceased Medicare beneficiaries age ≥65 with primary malignant brain tumor (PMBT) or secondary MBT (SMBT) receiving care within a southeastern cancer community network including academic and community hospitals from 2012-2015. Utilization of hospice and cancer-directed therapy and total Medicare expenditures in the last 30 days of life were calculated using generalized linear and mixed effect models, respectively. Results: Late (1-3 days prior to death) or no hospice care was received by 24% of PMBT (n = 383) and 32% of SMBT (n = 940) patients. SMBTpatients received late hospice care more frequently than PMBT patients (10% vs 5%, P = 0.002). Cancer-directed therapy was administered to 18% of patients with PMBT versus 25% with SMBT (P = 0.003). Nonwhite race, male sex, and receipt of any hospital-based care in the final 30 days of life were associated with increased risk of late or no hospice care. The average decrease in Medicare expenditures associated with hospice utilization for patients with PMBT was $-12,138 (95% CI: $-18,065 to $-6210) and with SMBT was $-1,508 (95% CI: $-3,613 to $598). Conclusions: Receiving late or no hospice care was common among older patients with malignant brain tumors and was significantly associated with increased total Medicare expenditures for patients with PMBT.
Authors: Justin E Bekelman; Scott D Halpern; Carl Rudolf Blankart; Julie P Bynum; Joachim Cohen; Robert Fowler; Stein Kaasa; Lukas Kwietniewski; Hans Olav Melberg; Bregje Onwuteaka-Philipsen; Mariska Oosterveld-Vlug; Andrew Pring; Jonas Schreyögg; Connie M Ulrich; Julia Verne; Hannah Wunsch; Ezekiel J Emanuel Journal: JAMA Date: 2016-01-19 Impact factor: 56.272
Authors: Betty R Ferrell; Jennifer S Temel; Sarah Temin; Erin R Alesi; Tracy A Balboni; Ethan M Basch; Janice I Firn; Judith A Paice; Jeffrey M Peppercorn; Tanyanika Phillips; Ellen L Stovall; Camilla Zimmermann; Thomas J Smith Journal: J Clin Oncol Date: 2016-10-28 Impact factor: 44.544
Authors: Wijnanda J Frenkel; Erika J Jongerius; Miranda J Mandjes-van Uitert; Barbara C van Munster; Sophia E de Rooij Journal: J Am Geriatr Soc Date: 2014-01-21 Impact factor: 5.562
Authors: Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley Journal: Lancet Date: 2016-09-04 Impact factor: 79.321
Authors: Elie K Mehanna; Paul J Catalano; Daniel N Cagney; Daphne A Haas-Kogan; Brian M Alexander; James A Tulsky; Ayal A Aizer Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Martin Proescholdt; Stephanie T Jünger; Petra Schödel; Karl-Michael Schebesch; Christian Doenitz; Tobias Pukrop; Julius Höhne; Nils-Ole Schmidt; Martin Kocher; Holger Schulz; Maximilian Ruge; Kevin König; Roland Goldbrunner; Stefan Grau Journal: Brain Sci Date: 2021-01-18
Authors: Rita C Crooms; Hung-Mo Lin; Sean Neifert; Stacie G Deiner; Jess W Brallier; Nathan E Goldstein; Jonathan S Gal; Laura P Gelfman Journal: J Palliat Med Date: 2021-06-24 Impact factor: 2.947